Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Issue 1 (10th October 2018)

• Record Type: Journal Article
• Authors: Wei, Wei; Jian, Pei‐En; Li, Shao‐Hua; Guo, Zhi‐Xing; Zhang, Yong‐Fa; Ling, Yi‐Hong; Lin, Xiao‐Jun; Xu, Li; Shi, Ming; Zheng, Lie; Chen, Min‐Shan; Guo, Rong‐Ping
• Is Part Of: Cancer communications. Volume 38:Issue 1(2018)
• Page Start: 1
• Page End: 12
• Publication Date: 2018-10-10
• Subjects: Solitary tumor -- Hepatocellular carcinoma -- Adjuvant therapy -- Transcatheter arterial chemoembolization -- Hepatectomy alone -- Microvascular invasion; Cancer -- Periodicals; Neoplasms; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 616.994005
• DOI: 10.1186/s40880-018-0331-y
• Languages: English
• ISSNs: 2523-3548

Abstract

Abstract: Background: The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma (HCC) patients with solitary tumor and microvascular invasion (MVI) is controversial. This trial evaluated the efficacy and safety of adjuvant transcatheter arterial chemoembolization (TACE) after hepatectomy versus hepatectomy alone in HCC patients with a solitary tumor ≥ 5 cm and MVI. Methods: In this randomized, open‐labeled, phase III trial, HCC patients with a solitary tumor ≥ 5 cm and MVI were randomly assigned (1:1) to receive either 1–2 cycles of adjuvant TACE after hepatectomy (Hepatectomy‐TACE) or hepatectomy alone (Hepatectomy Alone). The primary endpoint was disease‐free survival (DFS); the secondary endpoints included overall survival (OS) and adverse events. Results: Between June 1, 2009, and December 31, 2012, 250 patients were enrolled and randomly assigned to the Hepatectomy‐TACE group ( n = 125) or the Hepatectomy Alone group ( n = 125). Clinicopathological characteristics were balanced between the two groups. The median follow‐up time from randomization was 37.5 months [interquartile range 18.3–48.2 months]. The median DFS was significantly longer in the Hepatectomy‐TACE group than in the Hepatectomy Alone group [17.45 months (95% confidence interval [CI] 11.99–29.14) vs. 9.27 months (95% CI 6.05–13.70), hazard ratio [HR] = 0.70 (95% CI 0.52–0.95), P = 0.020], respectively. The median OS was also significantly longer in the Hepatectomy‐TACE group than in the Hepatectomy Alone group [44.29 months (95% CI 25.99–62.58) vs. 22.37 months (95% CI 10.84–33.91), HR = 0.68 (95% CI 0.48–0.97), P = 0.029]. Treatment‐related adverse events were more frequently observed in the Hepatectomy‐TACE group, although these were generally mild and manageable. The most common grade 3 or 4 adverse events in both groups were neutropenia and liver dysfunction. Conclusion: Hepatectomy followed by adjuvant TACE is an appropriate option after radical resection in HCC patients with solitary tumor ≥ 5 cm and MVI, with acceptable toxicity.